ReviewFrontiers in medicine2026
Contemporary management of sarcoidosis.
Review in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sarcoidosis is a heterogeneous multisystem granulomatous disease with a highly variable clinical course ranging from spontaneous resolution to progressive organ dysfunction and life-threatening complications. Treatment decisions are guided by symptom burden, organ involvement, risk of irreversible damage, and overall impact on patient health-related quality of life. Corticosteroids remain the cornerstone of therapy; however, concerns regarding long-term cumulative toxicity and limited effects on disease progression have driven increasing interest in steroid-sparing and targeted therapeutic approaches. Recent clinical trial data evaluating earlier use of methotrexate and evolving steroid-sparing strategies reflect a changing treatment paradigm in selected patients with sarcoidosis.This review provides an updated overview of contemporary sarcoidosis management, integrating current guideline recommendations, recent clinical trial data, steroid-sparing approaches, biologic therapies, antifibrotic treatment, and emerging targeted therapies. In addition, current challenges in disease monitoring, treatment selection, and future directions toward personalized medicine are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.